In summary, extensive clinical trials and empirical research studies have demonstrated the efficacy of PARP inhibitors in treating breast, ovarian, prostate, and pancreatic cancer, ushering in the acceptance of this treatment regimen as a viable option for targeted solid tumor therapy. This evidence concerns the gene PARP1 and pancreatic neoplasm.